EA202091977A1 - Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения - Google Patents

Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения

Info

Publication number
EA202091977A1
EA202091977A1 EA202091977A EA202091977A EA202091977A1 EA 202091977 A1 EA202091977 A1 EA 202091977A1 EA 202091977 A EA202091977 A EA 202091977A EA 202091977 A EA202091977 A EA 202091977A EA 202091977 A1 EA202091977 A1 EA 202091977A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bind
binding proteins
nkg2d
methods
application
Prior art date
Application number
EA202091977A
Other languages
English (en)
Inventor
Грегори П. Чан
Энн Ф. Чеунг
Ася ГРИНБЕРГ
Дхрув Кам Сетхи
Уилльям Хани
Бьянка Принц
Бредли М. Ланд
Original Assignee
Драгонфлай Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Драгонфлай Терапьютикс, Инк. filed Critical Драгонфлай Терапьютикс, Инк.
Priority claimed from PCT/US2019/018751 external-priority patent/WO2019164930A1/en
Publication of EA202091977A1 publication Critical patent/EA202091977A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Описаны мультиспецифические связывающие белки, которые связываются с раковыми клетками человека, экспрессирующими CD33 (Siglec-3), и уничтожают их, а также фармацевтические композиции и терапевтические способы, применимые для лечения рака, экспрессирующего CD33. Изобретение относится к мультиспецифическим связывающим белкам, которые связываются с раковыми клетками человека, экспрессирующими CD33, и проявляют высокую эффективность и максимальный лизис клеток-мишеней по сравнению с моноклональными антителами к CD33.
EA202091977A 2018-05-28 2019-02-20 Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения EA202091977A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862677137P 2018-05-28 2018-05-28
PCT/US2019/018751 WO2019164930A1 (en) 2018-02-20 2019-02-20 Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use

Publications (1)

Publication Number Publication Date
EA202091977A1 true EA202091977A1 (ru) 2021-02-09

Family

ID=68697331

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202091977A EA202091977A1 (ru) 2018-05-28 2019-02-20 Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
EA202092907A EA202092907A1 (ru) 2018-05-28 2019-05-28 Мультиспецифические связывающие белки и их усовершенствования

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202092907A EA202092907A1 (ru) 2018-05-28 2019-05-28 Мультиспецифические связывающие белки и их усовершенствования

Country Status (15)

Country Link
US (1) US20210214436A1 (ru)
EP (1) EP3802581A4 (ru)
JP (2) JP2021525731A (ru)
KR (1) KR20210013160A (ru)
CN (2) CN117964773A (ru)
AU (1) AU2019277138A1 (ru)
BR (1) BR112020024235A2 (ru)
CA (1) CA3101604A1 (ru)
CL (1) CL2020003071A1 (ru)
EA (2) EA202091977A1 (ru)
IL (1) IL278943A (ru)
MX (1) MX2020012905A (ru)
PE (1) PE20210167A1 (ru)
SG (1) SG11202011763YA (ru)
WO (1) WO2019231920A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3235295A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
HRP20211744T1 (hr) 2017-07-14 2022-02-04 Immatics Biotechnologies Gmbh Poboljšana molekula polipeptida dvostruke specifičnosti
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
SG11202007945UA (en) * 2018-02-20 2020-09-29 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
US20230242647A1 (en) * 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
MX2022013876A (es) * 2020-05-04 2023-02-09 Immunorizon Ltd Constructos de anticuerpos triespecificos precursores y metodos de uso de los mismos.
US20230365709A1 (en) * 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
WO2022143912A1 (zh) * 2020-12-31 2022-07-07 信达生物制药(苏州)有限公司 含异二聚体抗体Fc的蛋白以及其制备方法
IL308257A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Antigen binding proteins that uniquely bind PRAME
US20230116446A1 (en) * 2021-09-21 2023-04-13 Qilu Puget Sound Biotherapeutics Corporation HETERODIMERIC Fc FOR MAKING FUSION PROTEINS AND BISPECIFIC ANTIBODIES
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10156482A1 (de) * 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
AU2005291039A1 (en) * 2004-10-01 2006-04-13 Avidex Ltd. T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
ES2628075T3 (es) * 2011-12-19 2017-08-01 Synimmune Gmbh Molécula de anticuerpo biespecífica
JP6571527B2 (ja) * 2012-11-21 2019-09-04 ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドＷｕｈａｎ Ｙｚｙ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 二重特異性抗体
EA032681B1 (ru) * 2012-11-27 2019-07-31 Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
PL3227332T3 (pl) * 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
US20160176983A1 (en) * 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
EP3095792A1 (en) * 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
CA2990511A1 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific antigen binding proteins
US20180327499A1 (en) * 2015-11-13 2018-11-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
AU2018219887A1 (en) * 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019016424A2 (pt) * 2017-02-10 2020-04-07 Dragonfly Therapeutics Inc proteínas de ligação a bcma, nkg2d e cd16
CA3235295A1 (en) * 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
KR20190120775A (ko) * 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d 및 cd16에 결합하는 단백질
BR112020003050A2 (pt) * 2017-08-16 2020-09-01 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16, e egfr, hla-e, ccr4 ou pd-l1

Also Published As

Publication number Publication date
JP2024023438A (ja) 2024-02-21
CN117964773A (zh) 2024-05-03
AU2019277138A1 (en) 2020-12-17
WO2019231920A1 (en) 2019-12-05
CL2020003071A1 (es) 2021-05-24
CA3101604A1 (en) 2019-12-05
US20210214436A1 (en) 2021-07-15
KR20210013160A (ko) 2021-02-03
BR112020024235A2 (pt) 2021-05-04
IL278943A (en) 2021-01-31
PE20210167A1 (es) 2021-01-28
EA202092907A1 (ru) 2021-04-13
JP2021525731A (ja) 2021-09-27
EP3802581A1 (en) 2021-04-14
SG11202011763YA (en) 2020-12-30
EP3802581A4 (en) 2022-04-13
CN112533944A (zh) 2021-03-19
MX2020012905A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
EA202091977A1 (ru) Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
MX2020008684A (es) Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
EA202190468A1 (ru) Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
PH12017502129A1 (en) Antibodies against ox40 and uses thereof
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
EA201891121A1 (ru) Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
EA201692459A1 (ru) Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
EA201790060A1 (ru) Биспецифические cd33- и cd3-связывающие белки
EA202190773A1 (ru) CD1d ИММУНОГЛОБУЛИН ДВОЙНОГО ДЕЙСТВИЯ
MX2020008336A (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
CL2020002036A1 (es) Terapia de combinación del cáncer que incluye proteínas de unión multiespecíficas que activan a las células asesinas naturales
EA201792581A1 (ru) Способы применения биспецифических cd33- и cd3- связывающих белков
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
PH12019500571A1 (en) Anti-pd-1 antibodies
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
EA201891788A1 (ru) Антитела к фно-альфа и их функциональные фрагменты
EA202090372A1 (ru) Универсальные соединения авт и их применение
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
EA201591796A1 (ru) Антитела к cd52
EA202091974A1 (ru) Связывающие bcma антитела и их применение
EA202192654A1 (ru) Слитый белок, содержащий анти-мезотелин антитело, анти-cd3 антитело или анти-egfr антитело, биспецифическое или триспецифическое антитело, содержащие его, и их применения
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками